Drug intelligence / Profile preview

NBS-001

Development stage: Discontinued
Lead developer: Novintum Bioscience
Modality: Small Molecules

Overview

NBS-001 is a small molecule drug that was initially developed by Novintum Bioscience Ltd. Its primary therapeutic area was neoplasms (cancers). The specific molecular target, mechanism of action, and detailed pharmacological profile have not been publicly disclosed. The development of NBS-001 has been discontinued and it is no longer in active clinical development[1][4].

Beyond the preview

Go deeper on NBS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBS-001.

Explore the full profile